Limited data exist regarding treatment response prediction to oral disease-modifying therapies (DMTs) in multiple sclerosis (MS).
Objectives:
We assessed the capacity of available scoring systems to anticipate disease activity parameters in naïve relapsing–remitting MS (RRMS) patients initiating daily oral DMTs, hypothesizing that they exhibit different predictive potentials.
Methods:
We conducted a retrospective study and applied the Rio Score (RS), modified Rio Score (mRS), and MAGNIMS Score 12 months after DMT initiation. At 36 months, we examined their ability to predict evidence of disease activity (EDA) components and treatment failure by logistic regression analysis.
Results:
Notably, 218 patients (62.4% females) initiating dimethyl fumarate, teriflunomide, and fingolimod were included. At 36 months, the RS high-risk group predicted evidence of clinical activity (odds ratio (OR) 10 [2.7–36.9]) and treatment failure (OR 10.6 [3.4–32.5]) but did not predict radiological activity (OR 1.9 [0.7–5]). The mRS non-responders group did not predict EDA and treatment failure. RS, mRS, and MAGNIMS 0 categories showed significantly lower EDA and treatment failure than the remainder.
Conclusion:
Scoring systems present different predictive abilities for disease activity parameters at 36 months in MS patients initiating daily oral therapies, warranting further adjustments (i.e. introduction of fluid biomarkers) to depict disease activity status fully.
IaffaldanoPLucisanoGButzkuevenH, et al. Early treatment delays long-term disability accrual in RRMS: Results from the BMSD network. Mult Scler2021; 27(10): 1543–1555.
3.
BergamaschiRQuagliniSTavazziE, et al. Immunomodulatory therapies delay disease progression in multiple sclerosis. Mult Scler2016; 22(13): 1732–1740.
4.
BrownJWLColesAHorakovaD, et al. Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis [published correction appears in JAMA 2020;323(13):1318]. JAMA2019; 321(2): 175–187.
5.
KalincikTDioufISharminS, et al. Effect of disease-modifying therapy on disability in relapsing-remitting multiple sclerosis over 15 years. Neurology2021; 96(5): e783–e797.
6.
RíoJRoviraÀGasperiniC, et al. Treatment response scoring systems to assess long-term prognosis in self-injectable DMTs relapsing-remitting multiple sclerosis patients [published correction appears in J Neurol 2021]. J Neurol2022; 269(1): 452–459.
7.
RíoJCastillóJRoviraA, et al. Measures in the first year of therapy predict the response to interferon beta in MS. Mult Scler2009; 15(7): 848–853.
8.
SormaniMPRioJTintorèM, et al. Scoring treatment response in patients with relapsing multiple sclerosis. Mult Scler2013; 19(5): 605–612.
9.
SormaniMPGasperiniCRomeoM, et al. Assessing response to interferon-β in a multicenter dataset of patients with MS. Neurology2016; 87(2): 134–140.
10.
ThompsonAJBanwellBLBarkhofF, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol2018; 17(2): 162–173.
11.
SaccàFLanzilloRSignoriA, et al. Determinants of therapy switch in multiple sclerosis treatment-naïve patients: A real-life study. Mult Scler2019; 25(9): 1263–1272.
12.
GauthierSAGlanzBIMandelM, et al. Incidence and factors associated with treatment failure in the CLIMB multiple sclerosis cohort study. J Neurol Sci2009; 284(1–2): 116–119.
13.
NorborgHRiiseTMyhrKM, et al. Real-world discontinuation rate of teriflunomide and dimethyl fumarate in multiple sclerosis. Mult Scler J Exp Transl Clin2021; 7(2): 20552173211022027.
14.
AyrignacXBigautKPelletierJ, et al. First line treatment failure: Predictive factors in a cohort of 863 relapsing remitting MS patients. Mult Scler Relat Disord2021; 48: 102686.
15.
RomeoMMartinelliVRodegherM, et al. Validation of 1-year predictive score of long-term response to interferon-β in everyday clinical practice multiple sclerosis patients. Eur J Neurol2015; 22(6): 973–980.
16.
RíoJRuiz-PeñaJL. Short-term suboptimal response criteria for predicting long-term non-response to first-line disease modifying therapies in multiple sclerosis: A systematic review and meta-analysis. J Neurol Sci2016; 361: 158–167.
17.
GasperiniCProsperiniLTintoréM, et al. Unraveling treatment response in multiple sclerosis: A clinical and MRI challenge. Neurology2019; 92(4): 180–192.
18.
SormaniMPDe StefanoN. Defining and scoring response to IFN-β in multiple sclerosis. Nat Rev Neurol2013; 9(9): 504–512.
19.
RíoJRoviraÀTintoréM, et al. Disability progression markers over 6-12 years in interferon-β-treated multiple sclerosis patients. Mult Scler2018; 24(3): 322–330.
20.
RioJRoviraABlancoY, et al. Response to treatment with interferon beta in patients with multiple sclerosis. Validation of the Rio score. Rev Neurol2016; 63(4): 145–150.
21.
HyunJWKimSHJeongIH, et al. Utility of the Rio score and modified Rio score in Korean patients with multiple sclerosis. PLoS ONE2015; 10(5): e0129243.
22.
TintoreMRoviraÀRíoJ, et al. Defining high, medium and low impact prognostic factors for developing multiple sclerosis. Brain2015; 138(Pt7): 1863–1874.
23.
WattjesMPCiccarelliOReichDS, et al. 2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis. Lancet Neurol2021; 20(8): 653–670.
24.
KaunznerUWGauthierSA. MRI in the assessment and monitoring of multiple sclerosis: An update on best practice. Ther Adv Neurol Disord2017; 10(6): 247–261.
25.
BanwellBGiovannoniGHawkesC, et al. Editors’ welcome and a working definition for a multiple sclerosis cure. Mult Scler Relat Disord2013; 2(2): 65–67.
26.
GiovannoniGTurnerBGnanapavanS, et al. Is it time to target no evident disease activity (NEDA) in multiple sclerosis?Mult Scler Relat Disord2015; 4(4): 329–333.
27.
LuGBeadnallHNBartonJ, et al. The evolution of “no evidence of disease activity” in multiple sclerosis. Mult Scler Relat Disord2018; 20: 231–238.
28.
ProsperiniLMancinelliCHaggiagS, et al. Minimal evidence of disease activity (MEDA) in relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry2020; 91(3): 271–277.
29.
RuggieriSProsperiniLAl-ArajiS, et al. Assessing treatment response to oral drugs for multiple sclerosis in real-world setting: A MAGNIMS study. J Neurol Neurosurg Psychiatry2024; 95(2): 142–150.
30.
SormaniMPTruffinetPThangaveluK, et al. Predicting long-term disability outcomes in patients with MS treated with teriflunomide in TEMSO. Neurol Neuroimmunol Neuroinflamm2017; 4(5): e379.
31.
BosterAHawkerKRitterS, et al. Disease activity in the first year predicts longer-term clinical outcomes in the pooled population of the phase III FREEDOMS and FREEDOMS II studies (P7.239). Neurology2015; 84(14, suppl.): P7.239.
32.
WattjesMPRoviraÀMillerD, et al. Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis—Establishing disease prognosis and monitoring patients. Nat Rev Neurol2015; 11(10): 597–606.
33.
UherTSchaedelinSSrpovaB, et al. Monitoring of radiologic disease activity by serum neurofilaments in MS [published correction appears in Neurol Neuroimmunol Neuroinflamm 2020;8(1)]. Neurol Neuroimmunol Neuroinflamm2020; 7(4): e714.
34.
BenkertPMeierSSchaedelinS, et al. Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: A retrospective modelling and validation study. Lancet Neurol2022; 21(3): 246–257.
